Fluor Corporation is rated Buy due to its successful business transition, strong contract wins, and effective capital allocation. The company exited its $2.43 billion NuScale investment, using the proceeds to fund aggressive share repurchases targeting $1.4 billion in 2026 after reducing its float by 11% in 2025. Management expects a 10% growth in adjusted EBITDA for 2026, while Wall Street projects 26% EPS growth and 5.5% revenue growth. Fluor's strong backlog, new awards, and strategic positioning in key industry megatrends support confidence in continued top- and bottom-line growth.
The global autoimmune disease therapeutics market is projected to grow from $80.54 billion in 2025 to $137.85 billion by 2035, at a CAGR of 5.52%. Growth is fueled by rising autoimmune disease prevalence, advances in biologics, JAK inhibitors, monocl...
The Vancouver Chinatown Foundation and RBC are hosting Light Up Chinatown! 2026, a free two-day festival on August 8-9 along Columbia Street in Vancouver’s Chinatown. The event features exclusive food collaborations, live music performances, family a...
New research from iSeatz reveals that U.S. travelers are increasingly strategic about travel rewards programs, with 40% treating them as financial optimization tools and 60% belonging to multiple programs. Despite high enrollment, many travelers find...
BlackRock reported quarterly earnings per share of $13.91, surpassing analyst estimates of $12.69, and revenue of $7.08 billion, exceeding expectations of $6.73 billion. The company’s assets under management reached a record $15.3 trillion, a 22% inc...
A regional nonprofit health plan reduced its Transparency in Coverage machine-readable file (MRF) production time from 45 days to less than 24 hours by integrating TALON's platform directly with its claims administration system. This eliminated a com...
